Long-term Efficacy, Safety, and Immunogenicity of the Infliximab (IFX) Biosimilar, PF-06438179/GP1111, in Patients with Rheumatoid Arthritis After Switching from Reference IFX or Continuing Biosimilar Therapy: Week 54-78 Data From a Randomized, Double-Blind, Phase III Trial

Cohen, SB; Radominski, SC; Kameda, H; Kivitz, AJ; Tee, M; Cronenberger, C; Zhang, M; Hackley, S; Rehman, MI; von Richter, O; Alten, R

Cohen, SB (corresponding author), Metroplex Clin Res Ctr, Dallas, TX 75231 USA.

BIODRUGS, 2020; 34 (2): 197

Abstract

Objective Our objective was to evaluate the long-term efficacy, safety, and immunogenicity of the infliximab biosimilar, PF-06438179/GP1111 (PF-SZ-IFX......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索